Study guide
1.1 Maternal, Obstetric & Perinatal History
NBRC RRT-NPS Neonatal/Pediatric Specialist Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Neonatal and Pediatric Patient Assessment
1.1 Maternal, Obstetric & Perinatal History 1.2 Fetal Surveillance & Antepartum Diagnostics 1.3 Gestational Age & Baseline Neonatal Examination 1.4 Apgar, Respiratory Distress & Thoracic Assessment 1.5 Pediatric Assessment Triangle & Vital Signs 1.6 Neurologic Assessment, Respiratory Failure & Triage
2 Chapter 2: Diagnostic Evaluation & Gas Exchange Monitoring
2.1 Pulse Oximetry, Pre/Postductal & Transcutaneous Monitoring 2.2 Capnography, Waveforms & Dead-Space Evaluation 2.3 Arterial & Capillary Blood-Gas Sampling 2.4 Umbilical Lines, Acid-Base & Laboratory Evaluation 2.5 Chest Imaging & Airway Radiography 2.6 Pulmonary Function, Bronchoscopy & Specimen Diagnostics
3 Chapter 3: Airway Management & Secretion Clearance
3.1 Pediatric Airway Anatomy & ETT Sizing 3.2 Cuffed Airways, Intubation & Difficult-Airway Management 3.3 Tracheostomy Devices & Routine Care 3.4 Tracheostomy Emergencies, Speaking & Decannulation 3.5 Airway Suctioning Technique & Safety 3.6 Airway Clearance, Home Care & Discharge Planning
4 Chapter 4: Pharmacology & Medical Gas Therapy
4.1 Aerosol Physics & Delivery Devices 4.2 Respiratory & Systemic Pharmacology 4.3 Oxygen Interfaces & Delivery Systems 4.4 Oxygen Blenders, Targets & Toxicity 4.5 HFNC Physiology, Sizing & Flow 4.6 HFNC Indications, Monitoring & Escalation
5 Chapter 5: Shared Neonatal & Pediatric Pulmonary Disorders
5.1 Neonatal RDS Pathophysiology & Management 5.2 TTN, Pneumonia & the Neonatal Differential 5.3 Meconium Aspiration & PPHN 5.4 BPD, Apnea & Chronic Neonatal Lung Disease 5.5 Bronchiolitis, Croup & Epiglottitis 5.6 Asthma, Cystic Fibrosis & Foreign-Body Aspiration
6 Chapter 6: Resuscitation, Emergency Protocols & Patient Safety
6.1 NRP Cord Management, Initial Steps & Ventilation 6.2 NRP Corrective Steps, Compressions & Medications 6.3 PALS Assessment, CPR & Cardiac Arrest 6.4 PALS Dysrhythmia & Shock Management 6.5 Neonatal & Pediatric Transport 6.6 Patient Safety, Teamwork & Family-Centered Care
7 Chapter 7: Noninvasive & Conventional Mechanical Ventilation
7.1 Bubble CPAP & Neonatal NIV 7.2 Pediatric NIV, Interfaces & Failure Recognition 7.3 Conventional Ventilation Physics & Modes 7.4 Initial Settings & ABG-Guided Titration 7.5 Ventilator Scalars & Loops 7.6 Ventilator Dyssynchrony & Troubleshooting 7.7 Weaning Readiness & Spontaneous Breathing Trials 7.8 Extubation & Post-Extubation Airway Risk
8 Chapter 8: High-Frequency Ventilation & Advanced Modes
8.1 HFOV Mechanics & Gas Transport 8.2 HFOV Controls & Clinical Management 8.3 HFJV Circuit & Controls 8.4 HFJV Servo Pressure & Clinical Indications 8.5 NAVA, Edi & Proportional Support 8.6 APRV in Pediatric Respiratory Failure
9 Chapter 9: Specialty Inhaled Gases & Exogenous Surfactant Therapy
9.1 Inhaled Nitric Oxide: Mechanism, Indications & Dose 9.2 Inhaled Nitric Oxide: Toxicity, Monitoring & Weaning 9.3 Heliox Physics & Delivery 9.4 Volatile Anesthetic & Subambient Gas Therapy 9.5 Surfactant Biology, Products & Dosing 9.6 Surfactant Administration & Response
10 Chapter 10: Pediatric ARDS & Parenchymal Critical Illness
10.1 PALICC-2 Diagnosis & Severity 10.2 PALICC-2 NIV & Possible PARDS 10.3 PARDS Lung-Protective Ventilation 10.4 PARDS Refractory Hypoxemia & Adjuncts 10.5 PIE & Pneumothorax Recognition 10.6 Thoracic Decompression & Chest Drains
11 Chapter 11: Congenital Heart Disease & Hemodynamic Management
11.1 Left-to-Right Shunts & Qp/Qs Physiology 11.2 Acyanotic Lesions & Respiratory Management 11.3 Cyanotic Lesions & the Five Ts 11.4 Ductal Dependence, PGE1 & the Hyperoxia Test 11.5 Single-Ventricle Physiology & Staged Palliation 11.6 Gas Balancing, Hemodynamics & NIRS
12 Chapter 12: Advanced Critical Care: ECMO, Neurotrauma & Palliative Care
12.1 ECMO Candidacy & Modality 12.2 ECMO Circuit, Lung Rest & Anticoagulation 12.3 Neurotrauma, ICP & Ventilation 12.4 Neonatal Therapeutic Hypothermia & Respiratory Care 12.5 Death by Neurologic Criteria: Examination & Apnea Testing 12.6 DNC Timing, Ancillary Testing, Palliation & Donation
1.1 Maternal, Obstetric & Perinatal History
Key Takeaways Explain This Topic AI
Maternal diabetes increases neonatal hypoglycemia, hypertrophic cardiomyopathy, macrosomia, and respiratory-distress risk. Fetal-lung-maturity tests are imperfect and should not replace assessment of gestational age, symptoms, and the full perinatal picture.
A low biophysical profile is concerning for fetal compromise and requires prompt obstetric evaluation; the score must be interpreted with gestational age, individual components, fetal monitoring, and maternal status.
Prolonged rupture of membranes, maternal fever or suspected intra-amniotic infection, prematurity, and inadequate group-B-streptococcus prophylaxis are important early-onset sepsis risk factors.
Last updated: September 2026
1.1 Maternal, Obstetric & Perinatal History
Neonatal assessment begins long before the infant takes its first breath. For the neonatal and pediatric respiratory therapist, comprehensive knowledge of maternal medical history, obstetric complications, and prenatal diagnostic testing is critical for predicting delivery room resuscitation requirements and anticipating acute neonatal pulmonary pathophysiology.
Gravida and Para: The Obstetric Foundation
A woman's obstetric history is traditionally communicated using the Gravida/Para designation or the more granular TPAL classification system:
Gravida (G): The total number of confirmed pregnancies, regardless of gestational duration or clinical outcome, including the current pregnancy.
Para (P): The number of pregnancies that have reached viable gestational age (traditionally ≥ 20 \ge 20 ≥ 20 weeks or a fetal weight ≥ 500 g \ge 500\text{ g} ≥ 500 g credit), regardless of whether the fetus was born alive or stillborn. Multiple gestations (e.g., twins or triplets) count as a single parous delivery event.
The TPAL system breaks Para down into four distinct categories ( G_ P_T_P_A_L_ ):
T (Term deliveries): Births occurring at ≥ 37 weeks \ge 37\text{ weeks} ≥ 37 weeks gestation.
P (Preterm deliveries): Births occurring between 20 weeks 20\text{ weeks} 20 weeks and 36 weeks and 6 days 36\text{ weeks and } 6\text{ days} 36 weeks and 6 days gestation.
A (Abortions): Pregnancies terminating prior to 20 weeks 20\text{ weeks} 20 weeks gestation, encompassing spontaneous miscarriages and induced or therapeutic terminations.
L (Living children): The current count of living biological children.
Clinical Significance for the Neonatal Specialist
Grand Multiparity ( ≥ 5 \ge 5 ≥ 5 deliveries): Carries an increased risk of uterine atony, postpartum maternal hemorrhage, precipitous labor, placental abruption, and fetal malpresentation, increasing the likelihood of intrapartum fetal hypoxia.
Prior Preterm Delivery: A history of a prior preterm birth is the single strongest clinical predictor of recurrent preterm labor. When PPROM raises the likelihood of preterm delivery, prepare gestation-appropriate stabilization and respiratory equipment while also anticipating infection, cord, fluid, and pulmonary-development complications.
Maternal Age Extremes: Adolescent mothers ( < 18 years <18\text{ years} < 18 years ) face elevated risks of pregnancy-induced hypertension, premature delivery, low birth weight, and cephalopelvic disproportion. Advanced maternal age ( > 35 years >35\text{ years} > 35 years ) is strongly correlated with gestational diabetes, chronic maternal vascular disease, preeclampsia, placenta previa, and chromosomal aneuploidies (e.g., Trisomy 21).
Lack of Prenatal Care: Unmonitored pregnancies have a threefold higher incidence of low birth weight and a fivefold increase in neonatal mortality, frequently presenting with undetected maternal infections, structural anomalies, and unmanaged metabolic derangements.
Maternal Medical Conditions & Neonatal Pathophysiology
Maternal Complication Primary Pathophysiology Impact on Fetal Development Neonatal Complications & Delivery Room Action
Gestational Diabetes (GDM) / IDM Maternal hyperglycemia → \rightarrow → fetal hyperglycemia → \rightarrow → fetal hyperinsulinemia (Pedersen hypothesis) Macrosomia (LGA, weight > 90 th >90\text{th} > 90 th percentile), organomegaly, delayed pulmonary maturity Surfactant deficiency/RDS (insulin inhibits cortisol-mediated surfactant apoprotein synthesis), profound hypoglycemia, polycythemia, shoulder dystocia/phrenic nerve injury.
Preeclampsia / PIH Systemic endothelial dysfunction, abnormal spiral artery remodeling, generalized vasospasm Chronic uteroplacental insufficiency, chronic fetal hypoxia, asymmetric IUGR, oligohydramnios Preterm delivery, placental abruption. Neonatal hypermagnesemia from maternal MgSO 4 \text{MgSO}_4 MgSO 4 infusion → \rightarrow → hypotonia, apnea, and respiratory depression.
Chorioamnionitis Polymicrobial bacterial invasion of amniotic fluid, chorion, and amnion (ascending genital tract flora) Fetal inflammatory response syndrome (FIRS), intra-amniotic cytokine storm, funisitis Early-onset neonatal sepsis (EONS), septic shock, congenital pneumonia, Persistent Pulmonary Hypertension of the Newborn (PPHN), severe RDS.
Maternal Opioid Use Chronic transplacental passage of synthetic or natural opioids with fetal neuroreceptor binding Fetal growth restriction, chronic intrauterine hypoxia, intermittent withdrawal episodes Neonatal Abstinence Syndrome (NAS): hypertonia, tremors, tachypnea with respiratory alkalosis, autonomic dysregulation, feeding intolerance.
Gestational Diabetes Mellitus (GDM) & The Infant of a Diabetic Mother (IDM)
Maternal hyperglycemia results in excessive glucose transfer across the placenta. In response, the fetal pancreas produces excessive insulin ( Pedersen hypothesis ). Because insulin is the primary anabolic growth hormone in utero, the fetus develops macrosomia (Large for Gestational Age, birth weight > 4 , 000 g >4,000\text{ g} > 4 , 000 g or > 90 th >90\text{th} > 90 th percentile) with excessive subcutaneous fat deposition across the shoulders and trunk.
From a pulmonary perspective, fetal hyperinsulinemia directly antagonizes the stimulatory effect of endogenous cortisol on fetal type II pneumocytes. Insulin inhibits the transcription and synthesis of surfactant-associated proteins ( SP-A and SP-B ) and blocks the incorporation of choline into dipalmitoylphosphatidylcholine (DPPC). Consequently, IDM infants are at substantial risk for severe Respiratory Distress Syndrome (RDS) , even when delivered near term (37–38 weeks).
Other critical IDM sequelae include:
Postnatal Hypoglycemia: Cord clamping abruptly eliminates maternal glucose transfer while neonatal hyperinsulinism persists, precipitating a precipitous drop in blood glucose ( < 40 mg/dL <40\text{ mg/dL} < 40 mg/dL in the first 4 hours or < 45 mg/dL <45\text{ mg/dL} < 45 mg/dL thereafter). Severe hypoglycemia impairs cerebral metabolism and blunts diaphragmatic contractility.
Polycythemia & Hyperviscosity: Chronic fetal tissue hypoxia drives fetal erythropoietin secretion, raising venous hematocrit above 65 % 65\% 65% . Hyperviscosity impairs microvascular perfusion, predisposing the neonate to renal vein thrombosis and exacerbating pulmonary vascular resistance (PVR).
Hypertrophic Cardiomyopathy: Transient asymmetric septal hypertrophy can produce subaortic left ventricular outflow tract obstruction, worsening cardiogenic pulmonary edema.
Birth Trauma: Shoulder dystocia frequently causes brachial plexus traction injuries (Erb palsy, C5–C6) and phrenic nerve injury (C3–C5) , resulting in diaphragmatic paralysis and asymmetric thoracic excursion that mimics severe unilateral atelectasis.
Preeclampsia, PIH, and Maternal Magnesium Sulfate
Preeclampsia is characterized by new-onset hypertension (systolic ≥ 140 mmHg \ge 140\text{ mmHg} ≥ 140 mmHg or diastolic ≥ 90 mmHg \ge 90\text{ mmHg} ≥ 90 mmHg ) after 20 weeks gestation accompanied by proteinuria ( ≥ 300 mg/24 hr \ge 300\text{ mg/24 hr} ≥ 300 mg/24 hr ) or signs of maternal end-organ damage (thrombocytopenia, hepatic transaminitis, pulmonary edema, cerebral/visual disturbances). The underlying vascular dysfunction causes progressive placental infarction, reducing oxygen and nutrient delivery to the fetus, which culminates in Intrauterine Growth Restriction (IUGR) and oligohydramnios .
Interestingly, chronic intrauterine stress and placental ischemia stimulate fetal endogenous adrenal corticosteroid release, which can paradoxically accelerate fetal surfactant synthesis in some growth-restricted fetuses. However, when maternal magnesium sulfate ( MgSO 4 \text{MgSO}_4 MgSO 4 ) is infused for maternal seizure prophylaxis, magnesium readily crosses the placenta. The neonate cannot clear magnesium rapidly due to immature glomerular filtration. Neonatal hypermagnesemia antagonizes calcium at neuromuscular junctions, presenting in the delivery room as:
- Severe flaccid hypotonia
- Weak or absent spontaneous respiratory effort (apnea)
- Lethargy and hyporeflexia
- Poor suck and impaired deglutition
- Chorioamnionitis and Intra-Amniotic Infection
Chorioamnionitis is an acute inflammation of the fetal membranes and chorion, typically triggered by ascending genital bacteria following Prolonged Rupture of Membranes (PROM > 18 hours >18\text{ hours} > 18 hours ) . Clinical diagnostic criteria include:
Maternal fever (temperature ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C / 100.4 ∘ F 100.4^\circ\text{F} 100. 4 ∘ F )
Maternal leukocytosis ( > 15 , 000 / μ L >15,000/\mu\text{L} > 15 , 000/ μ L )
Maternal tachycardia ( > 100 bpm >100\text{ bpm} > 100 bpm ) and persistent fetal tachycardia ( > 160 bpm >160\text{ bpm} > 160 bpm )
Uterine fundal tenderness and purulent, foul-smelling amniotic fluid
Fetal aspiration of infected amniotic fluid leads directly to congenital pneumonia , alveolar destruction, and Early-Onset Neonatal Sepsis (EONS) , most commonly caused by Group B Streptococcus (GBS) , Escherichia coli , and Listeria monocytogenes . Inflammatory mediators provoke intense pulmonary vasoconstriction, precipitating Persistent Pulmonary Hypertension of the Newborn (PPHN) with refractory hypoxemia and right-to-left extrapulmonary shunting.
Maternal Substance Exposure & Neonatal Abstinence Syndrome (NAS)
Transplacental exposure to maternal substances significantly alters neonatal cardiopulmonary and neurobehavioral stability:
Opioids (Heroin, Methadone, Buprenorphine, Oxycodone): Discontinuation of maternal supply causes Neonatal Abstinence Syndrome (NAS) , usually emerging within 24 to 72 hours for short-acting opioids, or 5 to 7 days for methadone. Manifestations are quantified using the modified Finnegan Neonatal Abstinence Scoring Tool and include high-pitched continuous crying, severe tremors, hypertonicity, frantic uncoordinated sucking, vomiting, watery diarrhea, and tachypnea ( > 60 breaths/min >60\text{ breaths/min} > 60 breaths/min ) . The tachypnea is centrally mediated by opioid withdrawal and typically induces a respiratory alkalosis rather than primary parenchymal lung pathology.
Cocaine & Amphetamines: Potent maternal and placental vasoconstrictors. They induce acute fetal hypoxia, placental abruption, intrauterine growth restriction, microcephaly, and an elevated incidence of necrotizing enterocolitis (NEC).
Tobacco / Nicotine: Carbon monoxide elevates fetal carboxyhemoglobin, displacing oxygen from fetal hemoglobin, while nicotine constricts uterine arteries. This causes chronic placental insufficiency, low birth weight, and a threefold higher risk of Sudden Infant Death Syndrome (SIDS).